ARA-290 Cibinetide is a synthetic peptide drug consisting of 11 amino acids. This chemical compound is a derivative of the natural hormone erythropoietin (EPO). The main difference from regular EPO is that cibinetide activat...
ARA-290 Cibinetide is a synthetic peptide drug consisting of 11 amino acids. This chemical compound is a derivative of the natural hormone erythropoietin (EPO). The main difference from regular EPO is that cibinetide activates EPOR-βcR receptors, which provide pronounced effects of neuroprotection, restoration of nerve fibers and suppression of inflammatory processes, without stimulating the formation of new blood cells (hematopoiesis).
Mechanism of action
When ARA-290 is administered, the JAK2/STAT3 signaling pathway is stimulated. This pathway plays a key role in cell signaling and provides a number of important effects:
|
Protocol |
Dose/day |
Course |
|---|---|---|
|
Neuropathy |
2-4 mg |
1 time/day, 28 days |
|
Inflammation |
1-2 mg |
14-21 days |
|
Nasal spray (250 mcg/spray) |
500-1000 mcg (2-4 sprays) |
20 days |
-
Reduction of pro-inflammatory cytokine levels: By activating this pathway, the drug reduces the level of key inflammation-stimulating molecules, such as tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6). These substances often cause chronic inflammatory processes leading to damage of tissues and organs.
-
Restoration of small nerve fibers: Patients show a significant increase in intraepidermal nerve fiber density (IENFD), which contributes to the restoration of sensitivity and reduction of pain sensations.
-
Improvement of microcirculation efficiency: The state of the vascular endothelium improves, blood flow in small vessels normalizes, which improves tissue trophism and accelerates the healing process of injuries.
The metabolism of the drug is characterized by a relatively long half-life of about 20-30 hours, which allows maintaining a stable therapeutic effect.
Main indications for use
|
Area |
Effects |
|---|---|
|
Neuropathy |
Diabetic/sarcoid neuropathy (pain ↓ 50%, sensitivity ↑) |
|
Inflammation |
Chronic (colitis, dermatitis) |
|
Regeneration |
Nerves, vessels, tissues after injuries |
|
Heart |
Ischemia, CHF (EF↑) |
ARA-290 is used to treat a wide range of diseases associated with nervous system damage, inflammatory reactions and the need for accelerated tissue regeneration.
|
Stack |
Effect |
Dose |
|---|---|---|
|
ARA-290 + BPC-157 |
Neuroprotection+regen |
2 mg + 250 mcg |
|
ARA-290 + PE-22-28 |
Pain+stress (neuro) |
2 mg + 200 mcg |
|
ARA-290 + KPV |
Inflammation x2 |
2 mg + 500 mcg |
|
ARA-290 + TB-500 |
Nerves+tissues |
2 mg + 2.5 mg |
ARA-290 has a wide spectrum of positive effects, exerting a significant impact on the restoration of nerve conduction, reduction of inflammation and tissue regeneration.
Information
Smart Benefits.
Maximum Impact.
The Science of Longevity in Detail
